Provider of essential life science technologies for disease research and drug discovery selects clinivation WorldView as its most comprehensive, authoritative resource for building its medical product submissions and registrations worldwide.
Natick, MA, April 23, 2008 – clinivation, Inc. announced today that Invitrogen Corporation (NASDAQ: IVGN) has selected clinivation WorldView®
Online Regulatory Intelligence web service.”We are delighted that Invitrogen has selected clinivation WorldView as their source for worldwide regulatory intelligence,” said Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions. “Now Invitrogen will have on-demand access to country-specific forms, templates, and contacts to submit faster than ever before,” he continued.
Clinivation WorldView is your most comprehensive, authoritative, and up-to-date resource for building all of your medical device submissions and registrations worldwide. Clinivation WorldView also interoperates with clinivation Global® enterprise software to make building and tracking medical device submissions and registrations easier than ever before.
About Invitrogen Corporation
Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The Company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction.
Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology — placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of more than $1.15 billion in 2006.
For more information, please visit http://www.invitrogen.com.